I study how law shapes innovation in the life sciences, with a substantial focus on big data and artificial intelligence in medicine. I write about the intellectual property incentives and protections for data and AI algorithms, the privacy issues with wide-scale health- and health-related data collection, the medical malpractice implications of AI in medicine, and how FDA should regulate the use of medical AI.
Samuel K Handelman, Ph.D., is Research Assistant Professor in the department of Internal Medicine, Gastroenterology, of Michigan Medicine at the University of Michigan, Ann Arbor. Prof. Handelman is focused on multi-omics approaches to drive precision/personalized-therapy and to predict population-level differences in the effectiveness of interventions. He tends to favor regression-style and hierarchical-clustering approaches, partially because he has a background in both statistics and in cladistics. His scientific monomania is for compensatory mechanisms and trade-offs in evolution, but he has a principled reason to focus on translational medicine: real understanding of these mechanisms goes all the way into the clinic. Anything less that clinical translation indicates that we don’t understand what drove the genetics of human populations.
Srijan Sen, MD, PhD, is the Frances and Kenneth Eisenberg Professor of Depression and Neurosciences. Dr. Sen’s research focuses on the interactions between genes and the environment and their effect on stress, anxiety, and depression. He also has a particular interest in medical education, and leads a large multi-institution study that uses medical internship as a model of stress.
Matthew Kay, PhD, is Assistant Professor of Information, School of Information and Assistant Professor of Electrical Engineering and Computer Science, College of Engineering, at the University of Michigan, Ann Arbor.
Prof. Kay’s research includes work on communicating uncertainty, usable statistics, and personal informatics. People are increasingly exposed to sensing and prediction in their daily lives (“how many steps did I take today?”, “how long until my bus shows up?”, “how much do I weigh?”). Uncertainty is both inherent to these systems and usually poorly communicated. To build understandable data presentations, we must study how people interpret their data and what goals they have for it, which informs the way that we should communicate results from our models, which in turn determines what models we must use in the first place. Prof. Kay tackles these problems using a multi-faceted approach, including qualitative and quantitative analysis of behavior, building and evaluating interactive systems, and designing and testing visualization techniques. His work draws on approaches from human-computer interaction, information visualization, and statistics to build information visualizations that people can more easily understand along with the models to back those visualizations.
Joseph Ryan, PhD, is Associate Professor of Social Work, School of Social Work and Faculty Associate in the Center for Political Studies, ISR, at the University of Michigan, Ann Arbor.
Prof. Ryan’s research and teaching build upon his direct practice experiences with child welfare and juvenile justice populations. Dr. Ryan is the Co-Director of the Child and Adolescent Data, an applied research center focused on using big data to drive policy and practice decisions in the field. Dr. Ryan is currently involved with several studies including a randomized clinical trial of recovery coaches for substance abusing parents in Illinois (AODA Demonstration), a foster care placement prevention study for young children in Michigan (MiFamily Demonstration), a Pay for Success (social impact bonds) study focused on high risk adolescents involved with the Illinois child welfare and juvenile justice system and a study of the educational experiences of youth in foster care (Kellogg Foundation Education and Equity). Dr. Ryan is committed to building strong University and State partnerships that utilize big data and data visualization tools to advance knowledge and address critical questions in the fields of child welfare and juvenile justice.
Matthew Schipper, PhD, is Professor in the Departments of Radiation Oncology and Biostatistics. He received his Ph.D. in Biostatistics from the University of Michigan in 2006. Prior to joining the Radiation Oncology department he was a Research Investigator in the Department of Radiology at the University of Michigan and a consulting statistician at Innovative Analytics.
Prof. Schipper’s research interests include:
- Use of Biomarkers to Individualize Treatment – Selection of dose for cancer patients treated with Radiation Therapy (RT) must balance the increased efficacy with the increased toxicity associated with higher dose. Historically, a single dose has been selected for a population of patients (e.g. all stage III NSC lung cancer). However, the availability of new biologic markers for toxicity and efficacy allow the possibility of selecting a more personalized dose. I am interested in using statistical models for toxicity and efficacy as a function of RT dose and biomarkers to select an optimal dose for an individual patient. We are studying quantitative methods based on utilities to make this efficacy/toxicity tradeoff explicit and quantitative when biomarkers for one or multiple outcomes are available. We have proposed a simulation based method for studying the likely effects of any model or marker based dose selection on both toxicity and efficacy outcomes for a population of patients. In related projects, we are studying the role of correlation between the sensitivity of a patient’ tumor and normal tissues to radiation. We are also studying how to utilize these techniques in combination with baseline and/or mid-treatment adaptive image guided RT.
- Early Phase Oncology Study Design – An increasingly common feature of phase I designs is the inclusion of 1 or more dose expansion cohorts (DECs) in which the MTD is first estimated using a 3+3 or other Phase I design and then a fixed number (often 10-20 in 1-10 cohorts) of patients are treated at the dose initially estimated to be the MTD. Such an approach has not been studied statistically or compared to alternative designs. We have shown that a CRM design, in which the dose-assignment mechanism is kept active for all patients, more accurately identifies the MTD and protects the safety of trial patients than a similarly sized DEC trial. It also meets the objective of treating 15 or more patients at the final estimated MTD. A follow-up paper evaluating the role of DECs with a focus on efficacy estimation is in press at Annals of Oncology.
Michael Elliott is Professor of Biostatistics at the University of Michigan School of Public Health and Research Scientist at the Institute for Social Research. Dr. Elliott’s statistical research interests focus around the broad topic of “missing data,” including the design and analysis of sample surveys, casual and counterfactual inference, and latent variable models. He has worked closely with collaborators in injury research, pediatrics, women’s health, and the social determinants of physical and mental health. Dr. Elliott serves as an Associate Editor for the Journal of the American Statistical Association. He is currently serving as a co-investigator on the MIDAS-affiliated Reinventing Urban Transportation and Mobility project, working to develop methods to improve the representativeness of naturalistic driving data.
I am a data scientist, with extensive and various experience drawing inference from large data sets. In education research, I work to understand and improve postsecondary student outcomes using the rich, extensive, and complex digital data produced in the course of educating students in the 21st century. In 2011, we launched the E2Coach computer tailored support system, and in 2014, we began the REBUILD project, a college-wide effort to increase the use of evidence-based methods in introductory STEM courses. In 2015, we launched the Digital Innovation Greenhouse, an education technology accelerator within the UM Office of Digital Education and Innovation. In astrophysics, my main research tools have been the Sloan Digital Sky Survey, the Dark Energy Survey, and the simulations which support them both. We use these tools to probe the growth and nature of cosmic structure as well as the expansion history of the Universe, especially through studies of galaxy clusters. I have also studied astrophysical transients as part of the Robotic Optical Transient Search Experiment.
Jeremy Taylor, PhD, is the Pharmacia Research Professor of Biostatistics in the School of Public Health and Professor in the Department of Radiation Oncology in the School of Medicine at the University of Michigan, Ann Arbor. He is the director of the University of Michigan Cancer Center Biostatistics Unit and director of the Cancer/Biostatistics training program. He received his B.A. in Mathematics from Cambridge University and his Ph.D. in Statistics from UC Berkeley. He was on the faculty at UCLA from 1983 to 1998, when he moved to the University of Michigan. He has had visiting positions at the Medical Research Council, Cambridge, England; the University of Adelaide; INSERM, Bordeaux and CSIRO, Sydney, Australia. He is a previously winner of the Mortimer Spiegelman Award from the American Public Health Association and the Michael Fry Award from the Radiation Research Society. He has worked in various areas of Statistics and Biostatistics, including Box-Cox transformations, longitudinal and survival analysis, cure models, missing data, smoothing methods, clinical trial design, surrogate and auxiliary variables. He has been heavily involved in collaborations in the areas of radiation oncology, cancer research and bioinformatics.
I have broad interests and expertise in developing statistical methodology and applying it in biomedical research, particularly in cancer research. I have undertaken research in power transformations, longitudinal modeling, survival analysis particularly cure models, missing data methods, causal inference and in modeling radiation oncology related data. Recent interests, specifically related to cancer, are in statistical methods for genomic data, statistical methods for evaluating cancer biomarkers, surrogate endpoints, phase I trial design, statistical methods for personalized medicine and prognostic and predictive model validation. I strive to develop principled methods that will lead to valid interpretations of the complex data that is collected in biomedical research.
Johann Gagnon-Bartsch, PhD, is Assistant Professor of Statistics in the College of Literature, Science, and the Arts at the University of Michigan, Ann Arbor.
Prof. Gagnon-Bartsch’s research currently focuses on the analysis of high-throughput biological data as well as other types of high-dimensional data. More specifically, he is working with collaborators on developing methods that can be used when the data are corrupted by systematic measurement errors of unknown origin, or when the data suffer from the effects of unobserved confounders. For example, gene expression data suffer from both systematic measurement errors of unknown origin (due to uncontrolled variations in laboratory conditions) and the effects of unobserved confounders (such as whether a patient had just eaten before a tissue sample was taken). They are developing methodology that is able to correct for these systematic errors using “negative controls.” Negative controls are variables that (1) are known to have no true association with the biological signal of interest, and (2) are corrupted by the systematic errors, just like the variables that are of interest. The negative controls allow us to learn about the structure of the errors, so that we may then remove the errors from the other variables.